Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

BACKGROUND: Bevacizumab and the antimetabolites capecitabine and gemcitabine have been shown to improve outcomes when added to taxanes in patients with metastatic breast cancer. The primary aims of this trial were to determine whether the addition of capecitabine or gemcitabine to neoadjuvant chemot...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bear, Harry D., Tang, Gong, Rastogi, Priya, Geyer, Charles E., Robidoux, André, Atkins, James N., Baez-Diaz, Luis, Brufsky, Adam M., Mehta, Rita S., Fehrenbacher, Louis, Young, James A., Senecal, Francis M., Gaur, Rakesh, Margolese, Richard G., Adams, Paul T., Gross, Howard M., Costantino, Joseph P., Swain, Sandra M., Mamounas, Eleftherios P., Wolmark, Norman
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3401076/
https://ncbi.nlm.nih.gov/pubmed/22276821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1111097
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars